*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# JACOBIO PHARMACEUTICALS GROUP CO., LTD.

**加科思藥業集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1167)**

## VOLUNTARY ANNOUNCEMENT
## FURTHER INCREASE SHAREHOLDINGS OF THE PARTIES ACTING IN CONCERT

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company (the "**Shareholders**") and potential investors about the changes in the interests of the parties acting in concert of the Company (the "**Concert Parties**").

The board (the "**Board**") of directors (the "**Director(s)**") of the Company has been notified by members of the parties acting in concert of the Company that from July 24 to July 29, 2025, they continued to purchase a total of 60,900 shares of the Company (the "**Shares**") on the open market at an average price of HK$7.16 per Share. Immediately following the shareholding increase, as of the date of this announcement, the members of the parties acting in concert of the Company have recently purchased a total of 1,155,300 shares, and the Concert Parties holds a total of 200,755,285 shares of the Company, representing approximately 25.36% of the total issued shares of the Company.

The members of the Concert Parties expressed strong confidence in the Company's overall development prospects, growth potential, and the long-term investment value of its shares. Subject to compliance with applicable laws and regulatory requirements, they do not rule out the possibility of further increasing their shareholdings in the Company at an appropriate time.

Based on the information available to the Company and to the best of the Board's knowledge, this shareholding increase has been conducted in accordance with applicable laws, rules, and regulations, including the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By Order of the Board
**JACOBIO PHARMACEUTICALS GROUP CO., LTD.**
**Yinxiang WANG**
*Chairman*

Hong Kong, July 30, 2025

*As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr. Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.*